<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Proc. NatI. Acad. Sci. USA <br /> Vol. 86, pp. 3559-3563, May 1989 <br /> Biochemistry <br />  <br />  <br /> Peptide sequencing site-directed mutagenesis identify <br /> tyrosine-727 active site tyrosine Saccharomyces <br /> cerevisiae DNA topoisomerase I <br />      (vaccinia virus topoisomerase/camptothecin/phosphotyrosine/enzyme-DNA trans-esterification) <br /> RICHARD M. LYNN, MARY-ANN BJORNSTI*, PAUL R. CARON, AND JAMES C. WANG <br /> Department Biochemistry Molecular Biology, Harvard University, Cambridge, MA 02138 <br /> Contributed James C. Wang, February 1, 1989 <br />  <br /> <span id='am-1' about='protege:abstract' typeof='owl:Thing'>ABSTRACT</span>          Extensive digestion covalent interme-               resealing step reactions normally catalyzed topo- <br /> diate DNA Saccharomyces cerevisiae DNA topo-                     isomerases. The formation drug-topoisomerase-DNA <br /> isomerase I trypsin yields 7-amino acid peptide cova-                 ternary complex, inactivation enzyme <br /> lently linked DNA. Direct sequencing DNA-linked                    subsequent disruption essential cellular process, is <br /> peptide identifies Tyr-727 active site tyrosine forms            responsible cell killing drugs ofthis class (11-15). In the <br /> an 04-phosphotyrosine bond DNA enzyme                          case DNA topoisomerase I-specific drug camptothe- <br /> cleaves DNA phosphodiester bond. Site-directed mutagenesis                 cin, shown yeast cells killed drug <br /> of cloned yeast TOP) gene encoding enzyme confirms                   gene TOP] encoding DNA topoisomerase I, a <br /> the essentiality Tyr-727 relaxation supercoiled                nonessential enzyme yeast, expressed; mutant cells <br /> DNA enzyme. <span id='am-2' about='protege:FROM' typeof='owl:Thing'>From</span> amino acid sequence homology,                        devoid enzyme resistant drug (24, 27). <br /> Tyr-771 -773 readily identified active site                   Clearly, killing yeast TOP1+ cells camptothecin is <br /> tyrosines Schizosaceharomyces pombe human DNA                         inactivation enzyme consequence <br /> topoisomerase I, respectively. Sequence comparison site-                 formation cytotoxic drug-topoisomerase-DNA <br /> directed mutagenesis implicate Tyr-274 vaccinia virus                ternary complex. <br /> DNA topoisomerase active site residue. There appears                 <span id='am-4' about='protege:TO' typeof='owl:Thing'>To</span> understand catalysis DNA strand breakage and <br /> be 70-amino acid domain near carboxyl terminus                      rejoining topoisomerases certain drugs <br /> eukaryotic DNA topoisomerase I vaccinia topoisomerase,                   interfere trans-esterification reactions, have <br /> within active site tyrosine resides.                               undertaken mapping active site tyrosines in <br />                                                                              prokaryotic eukaryotic topoisomerases. We re- <br /> The participation DNA topoisomerases number                   cently reported results active sites Escherichia <br /> vital processes, including replication, transcription, genetic               coli DNA gyrase (DNA topoisomerase II), yeast DNA <br /> recombination, chromosomal decondensation, well-                      topoisomerase II (25, 26). In communication, report <br /> documented (for recent reviews, refs. 1-3; refs.                identification Tyr-727 active site tyrosine in <br /> 4-8). These enzymes catalyze transient breakage DNA                   Saccharomyces cerevisiae DNA topoisomerase I. In sep- <br /> strands form enzyme-mediated gates                       arate communication published elsewhere, show <br /> intact DNA strand pair DNA strands double helix                 Tyr-319 E. coli DNA topoisomerase I active site <br /> can pass. There distinct types DNA topo-                          tyrosine (R.M.L. J.C.W., unpublished data). Thus, the <br /> isomerases organisms examined date: type I                       active sites DNA breakage rejoining repre- <br /> enzyme forms gate strands                   sentative type I type II prokaryotic eukaryotic DNA <br /> duplex DNA, type II enzyme forms                         topoisomerases determined. By sequence com- <br /> double-stranded gate duplex DNA transiently cleaving                   parisons, active sites similar enzymes orga- <br /> both paired strands concert (refs. 1-3; refs.             nisms, ranging viruses human, deduced. <br /> 9 10). <br />    When DNA topoisomerase transiently breaks DNA <br /> backbone bond, simultaneously forms protein-DNA link,                                MATERIALS AND METHODS <br /> in tyrosyl oxygen enzyme joined DNA                     Materials, Bacterial Strains, Plasmids. E. coli K-12 <br /> phosphorus end enzyme-severed DNA strand                       strain NK7048 [(Alac pro)xiii ara nalA argEam thi rifR F&apos; <br /> (1-3). Reversal cleavage reaction restores DNA                    laclq&apos;] collection N. Kleckner (Harvard <br /> backbone bond frees enzyme additional reaction                   University); strain TG1 supplied Amersham. pBlue- <br /> cycles (1-3).                                                                script KS(+) purchased Stratagene. The lactone <br />    In past decade, number therapeutically important                 form drug camptothecin purchased Sigma. <br /> antibiotics antitumor agents target                  Yeast DNA topoisomerase I purified E. coli <br /> DNA topoisomerases (reviewed refs. 11-15). A large                        NK7048 cells harboring ptacTOP1, multicopy plasmid in <br /> fraction drugs characterized trapping               coding sequences yeast topoisomerase I are <br /> a class complexes DNA DNA topo-                               expressed trp-lac hybrid promoter Ptac (28). Expres- <br /> isomerases termed &quot;cleavable complexes.&quot; These com-                      sion yeast enzyme induced addition of <br /> plexes named cleavage DNA backbone                     isopropyl /3-D-thiogalactoside (IPTG) 1 mM. Cells were <br /> bonds, simultaneous formation DNA-enzyme                          harvested 3 hr induction lysed lysozyme-Brij <br /> links, revealed exposure protein denaturants                58 method. Polymin P precipitation, (NH4)2S04 precipitation <br /> (16-23). It likely drugs interfere DNA <br />                                                                              Abbreviation: IPTG, isopropyl B-D-thiogalactoside. <br /> The publication costs article defrayed page charge   *Present address: Department Biochemistry Molecular Biol- <br /> payment. This article marked &quot;advertisement&quot;         ogy, Institute Molecular Medicine, Jefferson Medical College, <br /> in accordance 18 U.S.C. &#194;&#167;1734 solely indicate fact.              Thomas Jefferson University, Philadelphia, PA 10917. <br />  3560     Biochemistry: Lynn et al.                                              Proc. Natl. Acad. Sci. USA 86 (1989) <br /> of proteins Polymin P supernatant phosphocellu-        phenol/chloroform/isoamyl alcohol mixture (50:49:1, <br /> lose chromatography according ref. 29,        vol/vol). The aqueous phase assay mixed with <br /> that (NH4)2SO4 cuts 40%o 80% saturation.         loading buffer containing Ficoll tracking dyes then <br /> In addition, buffers used purification procedure      loaded sample 1.1% agarose slab. Electropho- <br /> those described ref. 27. Pooled fractions phos-       resis 0.1 M Tris borate buffer 2 V/cm. <br /> phocellulose step chromatographed heparin- <br /> agarose described (29) purification yeast DNA                                  RESULTS <br /> topoisomerase II. Approximately 1.8 mg yeast DNA <br /> topoisomerase I purity &gt;90% obtained 6           Direct Sequencing DNA-Linked Tryptic Peptide S. <br /> liters E. coli culture.                                        cerevismae  DNA Topoisomerase I Identifies Tyr-727 the <br />    Preparation Yeast DNA Topoisomerase I-Derived           Active Site Tyrosine. An unambiguous way identifying the <br /> Tryptic Peptide Covalently Linked DNA. A 2.2-ml mixture        active site topoisomerase breakage rejoining <br /> containing 2.1 mg yeast DNA topoisomerase I, 300 pug        substrate form covalent enzyme-DNA com- <br /> EcoRI linearized pHC624, derivative pBR322, 10 mM            plex, digest complex endopeptidase, se- <br /> Tris HC1, pH 8.0/5 mM Na3EDTA/120 mM KCI/450 uM                   quence DNA-linked peptide. The peptide sequence <br /> camptothecin incubated 30&apos;C 10 min. SDS            directly reveals position DNA-linked amino acid in <br /> added 1% form covalent complex yeast            topoisomerase polypeptide chain (25-27). This method <br /> DNA topoisomerase I DNA, sample pre-              requires isolation sufficient DNA- <br /> cipitated sodium acetate ethanol.                        linked peptide amino acid sequencing. In case yeast <br />    Treatment alcohol-precipitated covalent complex         DNA topoisomerase I, preparation relatively large <br /> with trypsin, purification DNA-linked tryptic peptide,     DNA-linked peptide facilitated over- <br /> and amino acid sequencing DNA-linked peptide          production enzyme E. coli (28) enhancement <br /> carried according described procedures (25-27); over-      covalent complex formation enzyme and <br /> all recovery starting DNA -80%. William S. Lane        DNA presence drug camptothecin (20). <br /> of Harvard Microchemical Facility performed peptide          Fig. 1 illustrates formation covalent complex <br /> sequencing; assignment phenylthiohydantoin deriva-         yeast DNA topoisomerase I linear double- <br /> tives information peptide          stranded DNA (see Materials Methods details). Since <br /> being sequenced source protein.                            formation protein-DNA covalent link accom- <br />    Site-Directed Mutagenesis. A 326-<span id='am-5' about='xsp:base' typeof='owl:Thing'>base</span>-pair (bp) Spe I/Pst      panied breakage DNA backbone bond, extent <br />  I DNA fragment containing active site tyrosine codon      covalent complex formation estimated the <br /> the yeast TOP] gene obtained ptacTOP1          number scissions DNA strand. As shown lane 4, for <br /> cloned polylinker region plasmid pBluescript          mixture containing 2.1 mg yeast DNA topoisomerase I <br />  KS(+). A slightly larger Xba I/Pst I DNA fragment contain-       (=20 nmol) 300 Ag linear pHC624 DNA (0.5 nmol of <br />  ing entire 326 bp original TOP1 fragment then <br />  inserted Xba I Pst I sites polylinker                                  1 2 3 4 <br />  region double-stranded replicative form phage <br />  M13mpl9 DNA. The ligated DNA transformed E. <br />  coli strain TG1 individual white phage plaques on <br />  indicator plates containing 5-bromo-4-chloro-3-indolyl 03- <br />  D-galactopyranoside IPTG purified, checked the <br />  presence correct insert, used make single- <br />  stranded DNA site-directed mutagenesis. <br />     Specific amino acid substitutions yeast enzyme were <br />  accomplished oligonucleotide-directed method of <br />  Nakamaye Eckstein (30), using kit supplied Amer- <br />  sham. The oligonucleotides synthesized changing Tyr-727 <br />  phenylalanine serine, Asn-726 leucine, Ile-725 <br />  Asn-726 arginine alanine were, respectively, <br /> 5&apos;-AATCAATTTTATAGACCC-3&apos;, 5&apos;-AATCAATTCTAT- <br /> AGACCC-3&apos;, 5&apos;-CCAAAATCCT&apos;TTATATAGACCC-3&apos;, and <br /> 5&apos;-CCAAAATACCT&apos;T&apos;ATATAGACCC-3&apos;. Single-stranded <br /> DNA samples prepared purified phage plaques, and <br /> the presence desired base pair changes determined <br /> by nucleotide sequencing using kit supplied United States <br /> Biochemical. <br />   The double-stranded replicative form phage DNA was <br /> prepared, Spe I/Pst I DNA restriction fragment               FIG. 1.   Cleavage linearized pHC624 (2014 bp) yeast    DNA <br /> containing mutagenized region excised used          topoisomerase 20-,ul <br />                                                                                    I. A     reaction  mixture containing 3 tg pHC624 <br /> replace wild-type DNA fragment ptacTOP1.                    DNA, 18 ,ug topoisomerase I, 10 mM Tris-HCl, pH 8.0/120 mM <br />   Activity Assays. IPTG added final concentration      KCI/5 mM EDTA/450 mM camptothecin/5%              (vol/vol) dimethyl <br /> 1 mM 6-ml cultures optical densities 595 nm       sulfoxide incubated 300C 10 min. Then 2 ml 10% SDS <br /> were 0.3-0.5 induce expression yeast DNA topo-           added obtain covalent complex. The sample digested <br /> isomerase I. Cells harvested 2.5 hr induction,      proteinase K, phenol extracted, alcohol precipitated redis- <br />                                                                    solved, denatured alkaline, loaded lane 4 ofwere      1% <br /> extracts prepared described (28), 30 ,ul    alkaline-agarose gel. Samples loaded lanesDNA         as <br /> 2 M KCI added prior centrifugation extract.          follows: lane 1, HindIll restriction fragments phage A        used <br />   The relaxation negatively supercoiled DNA yeast            size markers; lane 2, linear pHC624 DNA; lane 3, that <br /> DNA topoisomerase I vitro assayed described (31).        loaded lane 4 DNA topoisomerase I omitted during <br /> Endogenous E. coli DNA topoisomerase I activity            incubation. Electrophoresis 1 V/cm 18 hr; gel was <br /> detectable assays. Each reaction terminated          stained ethidium neutralization,   photographed <br /> extracting mixture equal volume                   UV illumination. <br />           Biochemistry: Lynn et al.                                                 Proc. Natl. Acad. Sci. USA 86 (1989)            3561 <br />  <br /> strands), bulk 2-kilobase-pair DNA contains                         1    2    3    4     5    6 <br /> one scission strand. A densitometric           tracing the <br /> negative gel photograph showed afew percent <br /> of DNA strands remained intact, strand had <br /> several scissions average; thus, nanomole amounts the <br /> complex formed. Untreated DNA (lane 2), DNA <br /> mock-treated omission topoisomerase the <br /> initial reaction (lane 3), contained intact strands. <br />    Treatment covalent complex trypsin and <br /> sequencing DNA-linked peptide carried as <br /> summarized Materials Methods described in <br /> detail (25-27). The amino acids two <br /> cycles Edman degradation isoleucine asparagine. <br /> There assignable amino acid peaks cycle. <br /> The cycles contained isoleucine, aspartic acid, <br /> proline, arginine, &quot;blank,&quot; respectively. When se- <br /> quence compared published sequence yeast <br /> enzyme (32), readily concluded observed peptide <br /> sequencing <span id='am-6' about='xsp:pattern' typeof='owl:Thing'>pattern</span> corresponds exactly expected for <br /> the peptide Ile -Asn-Tyr727                           Tyr-727 <br /> being point covalent attachment DNA (and gave           FIG. 2. Relaxation supercoiled DNA wild-type mutant <br /> no assignable peaks Edman cycle). No              yeast DNA topoisomerase I. Extracts IPTG-induced E. coli cells <br /> sequences protein match 50o 7-amino         prepared relaxation 0.3 kug negatively supercoiled <br /> acid stretch. Furthermore, amino acid 724 yeast topoiso-          pHC624 DNA yeast DNA topoisomerase I extract was <br /> merase I lysine trypsin expected cleave         assayed described. Extracts obtained cells expressing <br /> after position, Arg-731, 7-amino   mutant yeast DNA topoisomerase I following substitutions: <br /> acid peptide linked DNA.                                          lane 1, Tyr-727 phenylalanine; lane 2, Tyr-727 serine; lane 3, <br />    Site-Directed Mutagenesis Yeast TOP) Gene Confirms         Asn-726 leucine; lane 4, Ile-725 Asn-726 arginine and <br />                                                                      alanine, respectively. Lane 5 contained DNA treated extract <br /> Essentiality Tyr-727 Catalysis. Mutating Tyr-727     cells expressing wild-type yeast DNA topoisomerase I, lane <br /> phenylalanine serine (described Materials Methods)         6 contained untreated pHC624 DNA. <br /> inactivates yeast DNA topoisomerase I, shown Fig. 2 <br /> (lanes 1 2). Extracts E. coli cells expressing            consensus sequence surrounding active site tyrosines <br /> wild-type yeast enzyme relaxed supercoiled DNA fully             eukaryotic type I enzymes Leu-Gly-Thr- <br /> (lane 5), 1/100th extract used assay         Ser-Lys-Ile-Asn-Tyr (active site), 5 7 amino acids <br />  shown. In experiments, absence activity         immediately preceding putative active site tyrosines are <br /> mutant cell extracts proteolysis yeast          dissimilar. Some amino acids eukaryotic con- <br /> enzymes. Immunostaining yeast DNA topoisomerase I                 sensus essential activity, however. Directly <br /> with specific antibodies showed extracts cells express-      preceding active site tyrosine, example, aspar- <br />  ing wild-type mutant proteins contained compara-         agine. When asparagine mutated leucine the <br /> ble amounts intact yeast DNA topoisomerase I (data            S. cerevisiae enzyme, resulting mutant enzyme remained <br /> shown).                                                              fully active, shown lane 3 Fig. 2. <br />   A Comparison Amino Acid Sequences Type I DNA                Thus, low degree homology exhibited amino <br /> Topoisomerases Yeasts, Human, Vaccinia Virus                acids surrounding Tyr-274 vaccinia enzyme those <br /> Identifies Active Site Tyrosines These Enzymes. The           surrounding active site tyrosines type I <br /> relatively high degree homology exhibited known            topoisomerases significant. To test possibility, <br /> amino acid sequences S. cerevisiae, S. pombe,             Ile-725 Asn-726 S. cerevisiae DNA topoisomer- <br /> human DNA topoisomerase I (32-34) makes straightfor-              ase I mutated arginine alanine the <br /> ward deduce Tyr-771 S. pombe enzyme               corresponding positions vaccinia topoisomerase. This <br /> Tyr-723 human enzyme homologous Tyr-727             mutated enzyme fully active (Fig. 2, lane 4). Thus, <br /> the S. cerevisiae enzyme active site           sequence yeast enzyme match the <br /> tyrosines enzymes.                                          environment presumed active site tyrosine vaccinia <br />   A type I topoisomerase particular           topoisomerase, activity retained. These results support <br /> found encapsidated vaccinia virus particles (35). This            assignment residue 274 active site tyrosine the <br /> enzyme unusual one-third size         vaccinia topoisomerase based homology search. <br /> typical eukaryotic type I DNA topoisomerase resistant <br /> to drug camptothecin (36, 37, 41). The vaccinia enzyme <br /> shows considerable amino acid sequence homology yeast                                      DISCUSSION <br /> and human DNA topoisomerase I, published                  The direct sequencing DNA-linked tryptic peptide of <br /> sequence comparison (36, 38) homologous regions           S. cerevisiae DNA topoisomerase I, coupled site- <br /> include residues corresponding active site tyrosines       directed mutagenesis data described Results, clearly iden- <br /> the eukaryotic topoisomerases described above.                       tify Tyr-727 active site tyrosine S. cerevisiae <br />   However, 30-amino acid region surrounding              enzyme. Sequence comparisons mutagenesis data also <br /> of active site tyrosines human yeast enzymes          permit assignment active site tyrosines other <br /> was used sequence similarity search using PROFILE          eukaryotic type I topoisomerases known sequences and <br /> program (39), low degree homology identifiable              strongly implicate Tyr-274 vaccinia virus-encoded <br /> between highly conserved yeast human sequences               enzyme active site residue. <br /> and vaccinia virus; Tyr-224 vaccinia enzyme              Fig. 3 depicts comparison amino acid sequences of <br /> appeared correspond Tyr-727 budding yeast (see          DNA topoisomerase I S. cerevisiae, S. pombe, human, <br /> Discussion). When residues surrounding Tyr-274 viral          vaccinia virus DNA topoisomerase. The active site <br /> enzyme Pro-Ser-Ile-Lys-Arg-Asn-Tyr274 compared              tyrosine region -70 amino acids shares <br />  3562        Biochemistry: Lynn et al.                                                                                                                   Proc. Natl. Acad. Sci. USA 86              (1989) <br />        Sp                                                                                                  MS SS DS VS LS[ I jE1R RQ RR GS S                             Kr1 ISM[R1E          D . 30 <br />         H MSGDHLHNDSQ                                  EADFRLNDSHKHKDKHKDREHSHKEHKKEKDKS[EK                                                                                    SOHL           N St 53 <br />  <br />        Sc                        MT I ArA SFV NHELSSDDDDDVPLSQTL R KIV A S 34 <br />        Sp ES[SSEN1PLS SL     K S K[SEED I P I KRRASSKKNMSN SSKK RAKV M 82 <br />         H HKID SEK  E <br />                    KEK DJKTKHD G SI   KHKIDHK D DKEKRK E EKVR G  I    E K 106 <br />  <br />        Sc M[iSAILQDEAEPYDS <br />                         K E1 ED1NE AI <br />        Sp GINGGLKNGKKTAVVK <br />                           D  E A I S KI S]KPTI <br />                                              S <br />                                                 jEPVQSS[                        87 <br />                                                 JHIKR1VSKANG[KNGJAIK1SAVKKEE SD 135 <br />                                                                                                                                                                   LPSPKAIK~ISATSE]P <br />         H ENGFFPSPPQ I KDEPE   GCY YPP     D I PL[KJPRDEDDADYKJK I ErE D TEK 159 <br />  <br />        Sc KE]IK2EDGDnKV2TTf   EE   N    KREEEEEED&amp;A <br />        Sp TDDSVPL RAVSTVS L rPYKS EL PSGAS T TONRSPNDE E <br />                                                                                                                                                            EE E E     K <br />                                                                                                                                                             ED Y K WwSE <br />                                                                                                                                                                         E   140 <br />                                                                                                                                                                          ID 188 <br />        H    E~gK RE]L E E E E D GEJL KIK P K N K D K D VPEPD N K K KEP                                                                                  KK EE E   KWW ERY P 212 <br />  <br />                I W VP <br />                TPY <br />             Sc[0~~~~~~_F      N GH             IH      dK        KPVDL                     I                             L Y Y D G                          PP OA EE VA GF F          A~ A          193 <br />  <br />        Sp [1KWT <br />           D T      TLLEH&#194;&#177;NGVIFAPPYEPLPIKINVKKL AYDGLJNIL                                                                                                    PPEAEEVAiGFrAA ML                       241 <br />         HE G I KWK   E                      KM YY DG  K                                                                                                       KAEEV                                 265 <br />  <br />  <br />           S|DHAKN                      VfQK                                                                                                 El KEF SRCDFTKMD                         LQLK E         246 <br />        Sc <br />        Sp TDHAK NPVFQDNF <br />                                    P               N   F       F       NL <br />                                                                FRDFLKVICDL <br />                                                                        V                                   FF <br />                                                                                                            CN <br />                                                                                                                S <br />                                                                                                                      jHtN. <br />                                                                                                                    GGPLnG                 . .IIKEFSKCDFT MFH                     F E QK R E         291 <br />              INFFK SWR <br />        HHEYTTKE                    KM                                    MI                                 E E        I      .       .   .    .          M       AEPT             K      E         314 <br />  <br />        ScQVDYKFUEL <br />             1SrQ E     R      F            JE                                                                                                           G N F KvF-        A   299 <br />        SpEK[ PIKEJKAK EKK D E E KY    LDGRKEK                                                                                                           GNF  EPPGLFRGRGSH 344 <br />        H                           ASK <br />                                     K EN <br />                                       F <br />                                       I L LKE <br />                                       L       Q FNR- R                                                                                                      NGRG N            367 <br />        V                                                                                                                                                      M R AL FYDI K L 11 <br />  <br />        SclP   K TG|KLKRR                     NPED0 V iLISKK 0 A P V               RH ON TV     M REN I                                                                                              352 <br />        Sp IPK <br />        H <br />                    TGISLKROR <br />                       MLKRR <br />                                             |YIPEOIE I <br />                                              MPE DI <br />                                                         Ni G              G <br />                                                                     PEPLPGH W AE V HDNTVTWLATIWIHIENII <br />                                                        INC K DAKVPStPPGHKWKEVRH D Nn TWL SWTENI <br />                                                                                                                                                                                                     397 <br />                                                                                                                                                                                                     420 <br />        V FTDNN                             PSDDNPAYEVLQHJ1JTHlJT D V V VVYLEO0rw E E AL      I FVGSDS                                                                                               64 <br />  <br />        Sc FmN   F     R     NSSLKGQSDYKKFEKAROLISY IDAI R D RN K KVL R 405 <br />        Sp NNN[VIK YVFLA GSS LK GOS DILKKYEK JRK |LKIDYI DDI R[ G IYRKD.L KIN EL T V RI 450 <br />         H OIG 3I K YMLYVMN SSIRJIKK <br />                                   EKRWL <br />                                     W        KRRKKcV        RNROYREDWK SKEKVR 473 <br />         V K fRRFYGKMHVHONRNARDR            RVYNVMKR NC         KN K     K*T D S N      115 <br />  <br />        Sc          W               YD                                      AE-                             DE| * | ADTVGCCSLRYEHVTLKPPN . .                                                     T V 451 <br />        Sp    R     AMY L I DVFALRAGNEKGIEDE- ADTVGCCSLRYEHVT&apos;LKPPR.T.V                                                                                                                              496 <br />         H IQ R ANV         IALRAGN EEn1ETA DVGCCSL                          NI1HPELDGQEYVrY                                                                                                         525 <br />         V            M ME TM F KI       F          g <br />                                              Y L KL-        SGL <br />                                                            VE.        K I E I              E I                                                                                    .   .   .         160 <br />        SciJFDFYLGVKVDVS      I R       T  EfQVFKNTPFKRPPKQ PHOLFDRR LDPS                  KYL                                                                                                       504 <br />                                                                      EG DLFO R L sfNSLN K Y Ll <br />        SPlIV F D F L G K D S IkRYY NE V E V D QV FK N LIK F KR PP KK LP                                                                                                                             549 <br />         H EIF Lf   L G K D S I R YLY       FVNVF  K N LG               EE Q  D   RLLGNHL|                                                                                                           577 <br />         V VI K FVVq                         s EN           LT        PE FI           RKVYEC                                                                                                         212 <br />        SCN MPG L TrA K V FMR       T Y N ASK TM          556 <br />                                                       DL I mN KG .S VAECK I L K <br />        Sp SLA      DGLQAKVFRTYNASYTMA               L DK 601      TLIAIK ILIFIYNRANRVA I LC <br />                                                             KNL * T <br />         H [MD L M EIGAKVFRTYNAS t1TL a[LKELTAPOENIA      630                 LSY NRANRAI2IJLC <br />         VKOF.                                  K.238 <br />                                                 N YNFWTN 28                                                                       .           ..   .   ..     .     ..     . <br />  <br />  <br />  <br />  <br />        SC NHQRT VTKGrHIAQTVKA N NROCL EEWK I RCKRA IL LDKDKDLIKEPKYFEE I 609 <br />        Sp NHQRSIVTKNWjDVQOMERFAERIKALOYIRMRLRKMMUJNJEPKLJAISKPELLAKE 654 652 <br />        H |N H RJAPP1idTF EKSMMNLQ TKjD...                                                                           .........                          ............. <br />  <br />  <br />  <br />  <br />        ScDDLTKEDEAT I KR I I DR[I [ YQR[KF 1VREN1DIRKFE- ELWLPES1QEKEW1E 661 <br />        SpEGITDSWIVKHHETLYELL K IEKK1KFDIRENERKLAAUPKSMLPESE        EVR K 707 <br />         H      ..............               . . .. <br />                                                 . . . <br />                                                    ........   .A.K  EQ   668 <br />                                                                           RRDLKSA      . <br />  <br />  <br />  <br />         V                  y- -.............................................. <br />        SC <br />        Sp A D <br />                                 0 EFEELKTGEP1ELKSSWNS WNSVKIKA QLE <br />                                 Q <br />                                    ADLDAL <br />                                KALAEK     KISKKSO P G RSS M EOEK <br />                                                               L <br />                                                                                         KE E714 <br />                                                                    RLN1KL JEERINVMRTIQOMMIDLEI 758                                                      LEQRIQTSSIQ7L <br />         HK A                        DA <br />                                 M K...K..V V        -.     .V S KKKAJ0R]LEE LMKLEVQAJITILEI 710 <br />                                                                            .   .   . <br />  <br />  <br />  <br />         V..    .   .   .   .   .   .   .   .   .           .       .   .   .   .   .   .       261 <br />                                                                                                .   .   .   .   .     . <br />                                                                                                                          ..   .       .JS I SPPSPKKLIALTIlTAL <br />       SC RSIV SIL GTSK I N Y I D PW_         R L|EV| KY|D V P I E K I F L|RE K FIKWA                                EN R             6 <br />       SP  IN KTTLGT         sNY II NY II DPRLTYSL K E DVPIEK1nLS K T RDKFNIWAWDITPPDWKW                            V A[               812 <br />        HSINHK11ALGISK <br />                   ~IA  LGT          DPRlmLtSVVKKYDlVP. <br />                                     YL          I    AW       K          I E K         KT       C FAWLMfD YE176 <br />                                                                                                      F    A   I DM          YE        765 <br />        V VVGHPT                 RAlMA ..TLf L E                 .KNF L              IS K TIFDCLS I VVDHVKSSTDG 314 <br />   FIG. 3. Alignment predicted protein sequences eukaryotic vaccinia virus DNA topoisomerase I. S. cerevisiae (Sc) S. pombe <br /> (Sp) sequences aligned using PROFILE program (39). Homology putative domains -30 amino acids long optimized.        The <br /> human sequence (H) aligned, followed alignment vaccinia virus sequence (V) sequences. Residues identical <br /> are boxed. Gaps inserted sequences indicated dots. The active site tyrosine S. cerevisiae enzyme predicted <br /> active sites enzymes marked asterisk. Amino acids designated single-letter <span id='am-3' about='Thesaurus:code' typeof='owl:Thing'>code</span>. <br /> some homology proteins. Eight residues, including                                                                             large gap (-160 amino acids long) 70-amino <br /> the active site tyrosine, conserved corresponding                                                                                  acid carboxyl-terminal region region upstream it <br /> positions region.                                                                                                                 strong homology polypeptides again <br />   As shown Fig. 3, vaccinia enzyme sequence                                                                               found. This suggests 70-amino acid carboxyl- <br />           Biochemistry: Lynn et al.                                                    Proc. Natl. Acad. Sci. USA 86 (1989)            3563 <br />  <br /> terminal region forms distinct domain yeast            6. Zhang, H., Wang, J. C. &amp; Liu, L. F. (1988) Proc. Natl. Acad. <br /> and human type I topoisomerases domain separated                     Sci. USA 85, 1060-1064. <br /> from domain &quot;linker&quot; peptides =160 amino acids                 7. Christman, M. F., Dietrich, F. S. &amp; Fink, G. R. (1988) Cell 55, <br />                                                                              413 <br /> </body></html>